Purpose. Patients with soft tissue sarcoma (STS) who have previously received standard chem otherapy including adriamycin (doxorubicin), ifosfamide, cyclophosphamide and DTIC (dacarbazine) have very limited therapeutic options. It is important to identify new drugs with some activity in this disease and we therefore undertook this trial to determine the antitumor activity of paclitaxel (Taxol). M eth ods. We conducted a phase II study of paclitaxel in patients with STS who had received prior standard chem otherapy. Paclitaxel was administered at a starting dose of 200 mg m 2 2 as a 24-h infusion with STS premedication, every 21 days or upon hematologic recovery (absolute granulocyte count (AGC) $ 1500/m l, platelets $ 100 000/m l).
Introduction
Paclitaxel (Taxol; Bristol-M eyers Squibb C o., Princeton, N J, U SA) is a novel antimicrotubule agent with a unique m echanism of action. It has been studied in a w ide variety of m alignancies with varyin g levels of ef® cacy.
1 G iven its`broad spectrum' activity, we perform ed a phase II study of paclitaxel in patients with soft tissue sarcom a (STS) w ho had received prior standard chem otherapy. Since leiomyosarcom as of gastrointestinal (G I) origin do not respond well to standard chemotherapy including adriam ycin and ifosfam ide, patients with this histology w ere eligible without prior exposure to chem otherapy. The m ajor objectives of the study w ere to evaluate the ef® cacy and the toxicity pro® le of paclitaxel in patients with ST S.
S ubjects and m ethods

E ligibility
Patients older than 16 years of age w ith histologic proof of a ST S were eligible. All patients had received prior standard chemotherapy including adriamycin, ifosfam ide, cyclophospham ide and D T IC (dacarbazine) with the exception of patients with G I leiomyosarcom a who could be chem otherapy naõ È ve. Patients were required to have a Zubrod perform ance status of 0± 2, a life expectancy of at least 12 weeks, m easurable or evaluable disease, and relatively norm al organ function de® ned as abso lute granulocyte count (AG C) of $ 1500/m l, platelet count of $ 100 000/m l, total bilirubin , 1.5 m g dl 2 1 serum creatinine , 1.6 m g dl 
Pretreatment evaluation and follow -up studies
Prior to enrolm ent on the protocol, all patients underwent a com plete history and physical examination. Laboratory studies included a com plete blood count (CBC) with differential and platelets, chemistry pro® le (SM A 12), electrolytes and m agnesium, repeated prior to each cycle. Appropriate radiographic studies were perform ed to de® ne the extent of tumor. A cardiac scan or 2D echocardiogram was perform ed to docum ent the cardiac ejection fraction prior to initiation of treatment. F ollowing paclitaxel, patients were followed with at least once weekly C BC w ith differential and platelet counts. C rosssectional radiographic im aging to assess response w as perform ed every two cycles.
Response criteria
C om plete response (CR) w as de® ned as the disappearance of all clinical evidence of tum or. Partial response (PR) was de® ned as a $ 50% reduction in the sum of the products of the biperpendicular diam eters of m easurable lesions without the app earance of new lesions for at least 3 weeks. Minor response (M R) was de® ned as a decrease in tum or size between 25 and 49% . Stable disease (SD) was de® ned as a , 25% change in the dim ensions of the tum or and progressive disease (PD ) w as de® ned as a # 25% increase in the sum of the perpendicular diam eters and/or appearance of new lesions. T um ors that could not be bidim ensionally m easured w ere deem ed evaluable. In these instance, regression, progression or no change were de® ned as unequivocal decrease, increase or no change in the tum or size and volum e as agreed upon by two independent investigators. D evelopm ent of new disease was also considered progression of disease.
Statistical considerations
T he trial was conducted in two stages, using the optim al two-stage design proposed by Sim on. 2 Based on the hypo thesis that a response rate of < 5% would be of no interest and a response rate of $ 20% would be signi® cant, 15 patients were required and 19 patients were entered in the ® rst stage of the study. If no responses were seen in these patients, the study would have to be term inated, otherwise a total of 35 patients needed to be accrued. T his design afford ed a power of 92% to detect a response rate of at least 20% with a rejection error of 10% .
Results
Patient characteristics
N ineteen patients were entered on the study ( Table  2) . The m edian age w as 50 years (range 20± 68 years). T here were nine fem ales and 10 m ales with a Zubrod perform ance status of 1 or 2. Eight patients had leiomyosarcom a, three had unclassi® ed sarcom a, three had strom al sarcom a of the breast, two had pleom orphic rhab dom yosarcom a, and one each had alveolar soft-part sarcom a, m alignant ® brous histiocytom a and synovial sarcom a. Seventeen patients had metastatic disease and tw o had persistent or locally recurrent disease. M edian num ber of cycles of paclitaxel chem otherapy adm inistered was tw o (range 1± 7).
Response
N o objective C R or PR w as seen. O ne patient with m etastatic lung disease from a high-grade strom al sarcom a of the breast had an M R. Seven other patients had SD while 11 patients had PD . 4 In this similar trial, we chose to evaluate the activity of pactitaxel at a dose of 200 m g m 2 2 administered as a 24-h infusion, every 3 weeks in patients failing prior treatment with standard chem otherapy. N o objective responses were noted in our trial suggesting a low level of activity of this drug in this patient population. A recently reported trial of paclitaxel in patients with previously untreated advanced ST S revealed a response rate of 12.5% . 5 T he patient population selected for our trial w as refractory to standard chem otherapy, and therefore less likely to respond to paclitaxel. Six patients had leiom yosarcom a of GI origin which did not respond to paclitaxel.
In conclusion, paclitaxel at a dose of 200 m g m over 24-h every 3 w eeks in patients w ith ST S refractory to standard chem otherapy is well tolerated but inactive. Phase II trials of new agents are w arranted.
